HCPConnect

For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Specialty Drug Updates

Pulmonology Clinical Coverage

Specialty-focused drug approvals, safety updates, trial context, and clinical reference coverage for healthcare professionals.

Clinical Coverage

Search drug updates and clinical coverage.

6 loaded
Pulmonology

Severe Asthma Biologics Comparison: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2026

Explore the comparative efficacy of severe asthma biologics: mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab insights for 2026.

May 14|2 min read|Dr. Nikhil Chatterjee
Pulmonology

Cytisinicline vs Varenicline: Comparative Efficacy in Smoking Cessation

Cytisinicline offers a 25% smoking cessation rate, comparable to varenicline and NRT, as highlighted by WHO's latest guidelines.

May 14|3 min read|Dr. Nikhil Chatterjee
Pulmonology

FDA Approves Dupilumab for COPD: 30% Exacerbation Reduction in BOREAS Trial

Dupilumab approved for COPD: 30% exacerbation reduction in BOREAS trial, addressing type 2 inflammation in patients.

May 6|3 min read|Dr. Nikhil Chatterjee
Pulmonology

FDA Approves Tezepelumab for Severe Asthma: 52% Exacerbation Reduction in NAVIGATOR Trial

Tezepelumab (Tezspire) approved for severe asthma: 52% exacerbation reduction in NAVIGATOR trial.

May 6|3 min read|Dr. Nikhil Chatterjee
Pulmonology

FDA Approves Depemokimab for Severe Asthma: New Eosinophilic Treatment Option

FDA approves depemokimab for severe asthma: a new eosinophilic treatment option for improved patient outcomes.

May 3|3 min read|Dr. Nikhil Chatterjee
Pulmonology

Severe Asthma Biologics: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2025

Explore the latest insights on severe asthma biologics: mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab for 2025.

Apr 29|3 min read|Dr. Nikhil Chatterjee

All current updates loaded